MedTrace Logo

Hormone Evaluation in Artificial Reproductive Technology

NCT03737253 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 810

Last updated 2025-03-17

No results posted yet for this study

Summary

The aim is to be able to predict the hormonal response according to gonadotropin receptor genotype and hormone type used for treatment of women undergoing in vitro fertilization or egg donation.

Outcome will be measured as pregnancy success, live born babies and unwanted side effects.

Conditions

  • Female Infertility

Interventions

DRUG

Follitropin alpha

The objective is to measure the effect of the drug according to gonadotropin receptor genotype.

DRUG

Menotropin

The objective is to measure the effect of the drug according to gonadotropin receptor genotype.

Sponsors & Collaborators

Principal Investigators

  • Yvonne Lundberg Giwercman, PhD · Lund University, Lund, Sweden

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2021-12-31
Completion
2024-10-02

Countries

  • Poland
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03737253 on ClinicalTrials.gov